Genefron Ltd. – Because the Response is Personal We are developing and producing the next generation of personal diagnostics kits. Our promise, forever to be kept, is to center the patient, focus on patient needs, ...Read More →
First pregnant women infected with CMV was tested by IFR 200 in AMC medical laboratory.
June 14-17, 2017
Genefron, Tel Aviv MC and the Hebrew University Publish an Abstract on EULAR Meeting Held in Madrid, Spain.>
The abstract presents prospective and retrospective results. The Conclusions: The Genefron diagnostic kit predicted the response to TNFα blockers in a high percentage of RA patients assessed either retrospectively or prospectively in a real life setting. This personal diagnostic kit has the ability to guide selection of a suitable biological drug for the individual RA patient. Want to read more?
Genefron received approval from the Israeli Health ministry (AMAR) for marketing IFR 100 kit. IFR 100 is a diagnostic kit for prediction of Multiple sclerosis (MS) patients response to Interferon beta treatment.
Genefron received approval from the Israeli Health ministry (AMAR) for marketing IFR 200 kit.
IFR 200 is a diagnostic kit for predicting the probability of congenital transmission CMV from pregnant women infected with the virus to the fetus.
Genefron received approval from the Israeli Health ministry (AMAR) for marketing IFR 300 kit
IFR 300 is a diagnostic kit for prediction of Rheumatoid arthritis (RA) patient's response to TNF blockers biologic treatment.
Breaking News - IFR 200
Genefron CMV Kit is available for the private sector to purchase.>
The IFR 200 is a new personalized medicine in vitro diagnostic kit for prediction the hCMV infected pregnant- women that will transmit the virus to fetus. The IFR 200 classifies the hCMV infected pregnant- women as either a transmitter or a Non transmitter.
ACR Poster Presentation
Genefron, Tel Aviv MC and the Hebrew University Publish a Poster Presentation at ACR meeting held in San-Francisco, USA. The Poster, presented by Prof. Elkayam, Dr. Faran & Dr.Smith was revealing a scientific breakthrough in personalized diagnostics and medicine. CONCLUSION - In this small group of patients, the Genefron diagnostic kit predicted the response to TNFα blockers and rituximab in a high percentage of patients. These preliminary results require further confirmation in large scale studies to assess whether this kit may possibly aid in the selection of a suitable biological drug for the individual RA patient.
Breaking News - IFR 300
Genefron RA kit is available for the private sector to purchase.
The IFR 300 is new personalized medicine in vitro kit developed based on analysis of large databases to predict the response of an individual to Anti TNF Biological treatment. The kit classifies RA biological naïve patients as responders or non-responders.
Genefron signed a contract with AMC medical laboratory to conduct the testing of pregnant women infected with CMV using IFR 200 kit.